{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:22:17Z","timestamp":1787898137280,"version":"build-2784847793"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018617","name":"Liaoning Revitalization Talents Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018617","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the levels of tumor-infiltrating CD8<jats:sup>+<\/jats:sup> lymphocytes (CD8<jats:sup>+<\/jats:sup> TILs) and the expression of programmed cell death receptor ligand 1 (PD-L1) in the tumor microenvironment (TME) of pediatric and adolescent pituitary adenomas (PAPAs) and analyze the correlation between their levels and the clinical characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A series of 43 PAPAs cases were enrolled over a period of 5 years. To compare the TME of PAPAs and adult PAs, 43 PAPAs cases were matched with 60 adult PAs cases (30 cases were between 20 and 40 years old, and 30 cases were older than 40 years) for main clinical characteristics. The expression of immune markers in PAPAs was detected by immunohistochemistry, and their correlation with the clinical outcomes was analyzed using statistical methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the PAPAs group, CD8<jats:sup>+<\/jats:sup> TILs level was significantly lower (3.4 (5.7) vs. 6.1 (8.5), p = 0.001), and PD-L1 expression (0.040 (0.022) vs. 0.024 (0.024), p &amp;lt; 0.0001) was significantly higher as compared with the older group. The level of CD8<jats:sup>+<\/jats:sup> TILs was negatively correlated with the expression of PD-L1 (r = \u22120.312, p = 0.042). Moreover, CD8<jats:sup>+<\/jats:sup> TILs and PD-L1 levels were associated with Hardy (CD8, p = 0.014; PD-L1, p = 0.018) and Knosp (CD8, p = 0.02; PD-L1, p = 0.017) classification. CD8<jats:sup>+<\/jats:sup> TILs level was associated with high-risk adenomas (p = 0.015), and it was associated with the recurrence of PAPAs (HR = 0.047, 95% CI 0.003\u20130.632, p = 0.021).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Compared with the TME in adult PAs, the TME in PAPAs was found to express a significantly altered level of CD8<jats:sup>+<\/jats:sup> TILs and PD-L1. In PAPAs, CD8<jats:sup>+<\/jats:sup> TILs and PD-L1 levels were associated with clinical characteristics.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1151714","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T10:21:42Z","timestamp":1687515702000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["PD-L1 and tumor-infiltrating CD8+ lymphocytes are correlated with clinical characteristics in pediatric and adolescent pituitary adenomas"],"prefix":"10.3389","volume":"14","author":[{"given":"Mengwu","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaochuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanhan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2020.04.002","article-title":"The epidemiology of pituitary adenomas","volume":"49","author":"Daly","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1227\/00006123-199502000-00004","article-title":"Pediatric pituitary adenomas","volume":"36","author":"Mindermann","year":"1995","journal-title":"Neurosurgery"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21430","article-title":"Primary pediatric brain tumors: statistics of Taipei VGH, Taiwan (1975-2004)","volume":"104","author":"Wong","year":"2005","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-199110000-00004","article-title":"Pediatric pituitary tumors","volume":"29","author":"Haddad","year":"1991","journal-title":"Neurosurgery"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00006123-199907000-00001","article-title":"Growth hormone-secreting pituitary adenomas in childhood and adolescence: features and results of transnasal surgery","volume":"45","author":"Abe","year":"1999","journal-title":"Neurosurgery"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-017-1769-8","article-title":"The 2017 world health organization classification of tumors of the pituitary gland: a summary","volume":"134","author":"Lopes","year":"2017","journal-title":"Acta Neuropathol."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B8","first-page":"12","article-title":"Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human glioma","volume":"7","author":"Dunn","year":"2007","journal-title":"Cancer Immun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03636-z","article-title":"Comprehensive analysis of the immunological landscape of pituitary adenomas: implications of immunotherapy for pituitary adenomas","volume":"149","author":"Zhou","year":"2020","journal-title":"J Neurooncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11060-018-2844-2","article-title":"The expression profile of PD-L1 and CD8(+) lymphocyte in pituitary adenomas indicating for immunotherapy","volume":"139","author":"Wang","year":"2018","journal-title":"J Neurooncol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-02145-y","article-title":"Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours","volume":"67","author":"Iacovazzo","year":"2020","journal-title":"Endocrine"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-015-9383-6","article-title":"Immune cell infiltrates in pituitary adenomas: more macrophages in larger adenomas and more T cells in growth hormone adenomas","volume":"26","author":"Lu","year":"2015","journal-title":"Endocr Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.5037","article-title":"Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer","volume":"29","author":"Mahmoud","year":"2011","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.6147","article-title":"In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer","volume":"27","author":"Pag\u00e8s","year":"2009","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-03-3259","article-title":"PD-L1\/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells","volume":"64","author":"Blank","year":"2004","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e660","DOI":"10.1016\/j.wneu.2020.09.031","article-title":"Analysis of cyclooxygenase 2, programmed cell death ligand 1, and arginase 1 expression in human pituitary adenoma","volume":"144","author":"Zhao","year":"2020","journal-title":"World Neurosurg"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8050695","article-title":"Analysis of tumor angiogenesis and immune microenvironment in non-functional pituitary endocrine tumors","volume":"8","author":"Sato","year":"2019","journal-title":"J Clin Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J Clin Invest."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and treatment of pituitary adenomas: a review","volume":"317","author":"Molitch","year":"2017","journal-title":"JAMA"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.162","article-title":"Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma","volume":"110","author":"Han","year":"2014","journal-title":"Br J Cancer."},{"key":"B24","article-title":"Quantification of histochemical staining by color deconvolution","volume":"23","author":"Ruifrok","year":"2001","journal-title":"Anal Quant Cytol Histol."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-022-05445-3","article-title":"Pediatric pituitary adenomas are more aggressive, more likely to be hormone producing and are more difficult to cure than adult pituitary adenomas: case series and systematic literature review","volume":"38","author":"Kelly","year":"2022","journal-title":"Childs Nerv Syst"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nlz040","article-title":"Pituitary adenoma in pediatric and adolescent populations","volume":"78","author":"Chen","year":"2019","journal-title":"J Neuropathol Exp Neurol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-017-3538-3","article-title":"A retrospective review of 34 cases of pediatric pituitary adenoma","volume":"33","author":"Zhang","year":"2017","journal-title":"Childs Nerv Syst"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3171\/2011.2.PEDS10278","article-title":"Microscopic endonasal transsphenoidal pituitary adenomectomy in the pediatric population","volume":"7","author":"Tarapore","year":"2011","journal-title":"J Neurosurg Pediatr"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1159\/000381862","article-title":"Transnasal transsphenoidal surgical method in pediatric pituitary adenomas","volume":"50","author":"Ta\u015fkap\u0131l\u0131o\u011flu","year":"2015","journal-title":"Pediatr Neurosurg"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1116","article-title":"Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations","volume":"24","author":"Kugel","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s40478-019-0830-3","article-title":"Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours","volume":"7","author":"Marques","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2014.11.005","article-title":"Aging disturbs the balance between effector and regulatory CD4+ T cells","volume":"60","author":"van der Geest","year":"2014","journal-title":"Exp Gerontol."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0144-8","article-title":"PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2018.09.004","article-title":"Biochemical aspects of PD-L1 regulation in cancer immunotherapy","volume":"43","author":"Zhang","year":"2018","journal-title":"Trends Biochem Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3171\/jns.2002.96.2.0195","article-title":"The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery","volume":"96","author":"Meij","year":"2002","journal-title":"J Neurosurg"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s10143-014-0525-y","article-title":"Invasive adenoma and pituitary carcinoma: a SEER database analysis","volume":"37","author":"Hansen","year":"2014","journal-title":"Neurosurg Rev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0228","article-title":"Aggressive and malignant pituitary tumours: state-of-the-art","volume":"25","author":"Dworakowska","year":"2018","journal-title":"Endocr Relat Cancer."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1227\/00006123-199310000-00008","article-title":"Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings","volume":"33","author":"Knosp","year":"1993","journal-title":"Neurosurgery"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1017\/s0317167100030055","article-title":"Surgical management of giant pituitary adenomas","volume":"17","author":"Mohr","year":"1990","journal-title":"Can J Neurol Sci"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s42000-021-00333-y","article-title":"High-risk pituitary adenomas and strategies for predicting response to treatment","volume":"21","author":"Kontogeorgos","year":"2022","journal-title":"Hormones (Athens)."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa449","article-title":"The immune profile of pituitary adenomas and a novel immune classification for predicting immunotherapy responsiveness","volume":"105","author":"Wang","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.6.3890","article-title":"IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk","volume":"166","author":"Strasly","year":"2001","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.nec.2019.05.006","article-title":"Management of nonfunctioning recurrent pituitary adenomas","volume":"30","author":"Farrell","year":"2019","journal-title":"Neurosurg Clin N Am"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science"},{"key":"B46","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12957-021-02272-9","article-title":"Research advances on the immune research and prospect of immunotherapy in pituitary adenomas","volume":"19","author":"Nie","year":"2021","journal-title":"World J Surg Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12916-021-02006-4","article-title":"Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors","volume":"19","author":"Wang","year":"2021","journal-title":"BMC Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1227\/neu.0000000000002024","article-title":"Complete response of a patient with a mismatch repair deficient aggressive pituitary adenoma to immune checkpoint inhibitor therapy: a case report","volume":"91","author":"Shah","year":"2022","journal-title":"Neurosurgery"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14645","article-title":"Should pituitary carcinoma be treated using a NET-like approach? a case of complete remission of a metastatic malignant prolactinoma with multimodal therapy including immunotherapy","volume":"98","author":"Goichot","year":"2023","journal-title":"Clin Endocrinol (Oxf)."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab133","article-title":"Synergism of checkpoint inhibitors and peptide receptor radionuclide therapy in the treatment of pituitary carcinoma","volume":"5","author":"Lin","year":"2021","journal-title":"J Endocr Soc"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10030088","article-title":"Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas: two case reports and a review of the literature","volume":"10","author":"Duhamel","year":"2020","journal-title":"J Pers Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001532","article-title":"Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study","volume":"8","author":"Majd","year":"2020","journal-title":"J Immunother Cancer."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0647","article-title":"Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study","volume":"187","author":"Ilie","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1151714\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T10:21:49Z","timestamp":1687515709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1151714\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":54,"alternative-id":["10.3389\/fendo.2023.1151714"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1151714","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]},"article-number":"1151714"}}